PTC Therapeutics Insider Sale Reduces Director Holdings to 17,451 Shares

Rhea-AI Filing Summary

PTC Therapeutics insider sale disclosed: Director Allan Steven Jacobson reported a sale of 1,667 shares of PTC Therapeutics (PTCT) on 08/28/2025 at a price of $50.15 per share, reducing his beneficial ownership to 17,451 shares. The Form 4 was signed by an attorney-in-fact on 09/02/2025. The filing is a routine Section 16 disclosure showing an individual director executed a non-derivative sale.

Positive

• Transparent disclosure of the sale date, price, and resulting beneficial ownership complying with Section 16 reporting requirements
• Post-transaction holdings disclosed: the filing states the director retains 17,451 shares after the sale

Negative

• Insider sale reported: 1,667 shares were sold, which may be interpreted by some investors as a reduction in insider holdings
• No contextual information provided about the reason for the sale or its relation to a trading plan

Insights

Financial Analyst

TL;DR: Routine director sale with clear disclosure; not obviously material without broader ownership context.

The Form 4 documents a single non-derivative sale of 1,667 common shares at $50.15 on 08/28/2025 by a company director, leaving 17,451 shares beneficially owned. This is a straightforward disclosure that provides price and post-transaction holdings, which helps maintain market transparency. Without additional context on total outstanding shares or other insider activity, the transaction does not on its own indicate a material change to company control or financial condition.

Corporate Governance Expert

TL;DR: Properly executed Section 16 disclosure; signature by attorney-in-fact is acceptable for timely reporting.

The filing identifies the reporting person as a director and shows the Form 4 was executed via attorney-in-fact, dated 09/02/2025. The disclosure meets Section 16 requirements by reporting the sale date, price, and resulting beneficial ownership. This is a routine governance compliance item; no amendments or additional explanatory notes accompany the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacobson Allan Steven

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/28/2025		S		1,667	D	$50.15	17,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Avraham S. Adler, Attorney-in-Fact	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for PTCT report?

The Form 4 reports a sale of 1,667 common shares of PTCT at $50.15 per share on 08/28/2025 by director Allan Steven Jacobson, leaving 17,451 shares beneficially owned.

Who is the reporting person on the PTCT Form 4?

The reporting person is Allan Steven Jacobson, identified as a director of PTC Therapeutics.

When was the PTCT transaction executed and when was the Form 4 signed?

The transaction date is 08/28/2025 and the Form 4 was signed by an attorney-in-fact on 09/02/2025.

Does the PTCT Form 4 show any derivative transactions or other security types?

No; the filing reports a non-derivative common stock sale only and contains no derivative transactions.

How many shares does the director own after the reported PTCT sale?

The director beneficially owns 17,451 shares following the reported transaction.